Whalesbook
So, Max Healthcare ke liye ek taraf badi financial relief aayi hai. Tax authorities ne company par lagai ₹55.20 Crore ki GST demand puri tarah se wapas le li hai. Delhi ke GST Officer ne April 2026 mein yeh order pass kiya. Yeh amount interest aur penalties ke saath tha. Asal mein, December 2025 mein company ko ₹33.66 Crore ki demand aayi thi, jisme interest add karke yeh figure ₹55.20 Crore tak pahunch gaya tha. Company ne input tax credit ke issues par effective arguments diye, jisse yeh tax dispute finally resolve ho gaya. Ab company par financial burden nahi hai aur woh apni growth strategies par pura focus kar sakti hai.
Aur dusri taraf, Max Healthcare ne ek major acquisition bhi ki hai. Company ne Odisha ke Bhubaneswar mein sthit Kalinga Hospital Ltd mein 58.4% controlling stake ₹300 Crore mein khareed liya hai. Yeh deal company ko East India market mein entry dila rahi hai aur ek 250-bed wala multi-specialty hospital group mein add ho jayega. Is deal ke liye paisa Standard Chartered Bank se loan lekar arrange kiya gaya hai, aur yeh lagbhag 4-6 weeks mein complete ho jayegi. Kalinga Hospital, jo 1997 mein bana tha, 10-acre land par hai aur future expansion ke liye bhi kaafi scope rakhta hai. Max Healthcare, Kalinga Hospital ke upgrades aur expansion ke liye ₹100 Crore tak ka loan bhi provide karega.
Ab agar valuations ki baat kare toh, Max Healthcare ka P/E ratio lagbhag 67.6x se 71.3x ke beech mein chal raha hai. Yeh apne rivals jaise Apollo Hospitals (around 61.4x P/E) aur Fortis Healthcare (61.8x se 69.6x P/E) ke aas-paas hi hai. Indian healthcare sector ka average P/E ratio 52.87 se 68.4 ke beech mein hai, jo sector mein strong growth expectations dikhata hai. Max Healthcare ka market cap ₹99,000 se ₹1,00,000 Crore ke aas-paas hai, jo company ki market mein leadership position ko represent karta hai.
However, kuch risks bhi hain jin par nazar rakhni hogi. Kalinga Hospital ko successfully integrate karna aur planned renovations ko execute karna ek challenge ho sakta hai. Company ka valuation bhi kaafi high hai, toh agar growth targets meet nahi hue toh share price mein zyada rally nahi dikhegi. Debt ka use bhi ek factor hai, especially agar interest rates mein bada badlav aata hai. Tax issue solve ho gaya hai, par regulators ka scrutiny dobara na ho, yeh bhi ek consideration hai.
Par analysts ka overall outlook kaafi positive hai. Aksar analysts 'Buy' rating de rahe hain aur unka average target price 23.50% tak ka upside dikha raha hai. UBS jaise analysts ne toh pehle hi ₹1,550 ka target diya tha. Company ka strategy, jaise capacity badhana, tax issues clear karna, aur nayi markets mein enter karna, sab milakar India ke badhte healthcare sector se fayda uthane ke liye well-positioned lagti hai.